-

Thermo Fisher Scientific Announces a New In-line Metrology Solution to Improve Battery Safety and Performance

Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer Delivers Real-time, Full-Coverage Mass Loading Analysis for Battery Electrode Coating

WALTHAM, Mass.--(BUSINESS WIRE)--To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently. The LInspector Edge analyzer introduces the next generation of metrology capabilities through a new analytical technique, in-line mass profilometry, measuring complete edge-to-edge coating profiles in milliseconds with unprecedented resolution and precision.

Uniform, defect-free coatings are essential for superior battery performance, for the attainment of higher charge densities, faster recharge times, longer operational lifetime, and better reliability. Traditional in-line coating weight measurement gauges use a single spot sensor traversing across the electrode sheet to assess coating quality, but several meters of electrode are produced in the time it takes to complete a single profile scan and much of the electrode goes unmeasured. In contrast, the LInspector Edge In-line Mass Profilometer measures the entire electrode in real-time, at full production speed offering more complete insights for battery manufacturers.

“Superior batteries, particularly for electric vehicles, are critical to society’s planned transition to clean energy,” said Miguel Faustino, president of Chemical Analysis at Thermo Fisher Scientific. “We are committed to providing battery manufacturers with analytical technology to meet this challenge and are excited to be able to offer this significant step forward in quality assurance capabilities. The LInspector Edge In-line Mass Profilometer sets a new benchmark for electrode coating analysis and provides a foundation for higher performance batteries, reduced risk to quality, better process control, and more profitable operation.”

Thanks to a greater insight into mass loading of active material on the coating edges and a complete mapping of mass loading on the entire electrode, battery manufacturers can now benefit from previously unobtainable richness of data for production control and full traceability for each electrode patch, stripe, or roll, allowing them to meet increasingly stringent quality requirements for energy storage devices.

In the past, the battery industry relied on industry standard coating weight scanning technologies, which typically only inspect the loading on a small fraction of the electrode surface area. According to an industry innovator and beta user, “Thermo Fisher Scientific's new technology enables the inspection of 100% of the area of all electrodes manufactured, eliminating blind spots in the data and reducing the risk of defects reaching the final product.”

First in a new generation of battery process metrology tools, the LInspector Edge In-line Mass Profilometer is supported by the Thermo Fisher global network of experts. Find out how it could improve your electrode coating process at: www.thermofisher.com/LinspectorEdge

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Ellen James
Thermo Fisher Scientific
Ellen.James@thermofisher.com
+1 (206) 348-4954

Thermo Fisher Scientific

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ellen James
Thermo Fisher Scientific
Ellen.James@thermofisher.com
+1 (206) 348-4954

More News From Thermo Fisher Scientific

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom